Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings results today. Total revenues inched up 1% to $11.5 billion versus the same period a year ago. Net earnings attributable to BMS were $1.76 billion, or $0.87 per share, compared to $2 billion, or $0.95 per share, last year. Adjusted EPS decreased 7% to $1.70. […]
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings results today. Total revenues inched up 1% to $11.5 billion versus the same period a year ago. Net earnings attributable to BMS were $1.76 billion, or $0.87 per share, compared to $2 billion, or $0.95 per share, last year. Adjusted EPS decreased 7% to $1.70. […]
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings results today.
Total revenues inched up 1% to $11.5 billion versus the same period a year ago.
Net earnings attributable to BMS were $1.76 billion, or $0.87 per share, compared to $2 billion, or $0.95 per share, last year. Adjusted EPS decreased 7% to $1.70.
For full-year 2024, the company expects revenues to increase by low single-digits and adjusted EPS to range between $7.10-7.40.
